---
$id: https://graph.org.ai/products/commodity/51142534
$type: Product
source: UNSPSC
code: "51142534"
title: "Mofegiline"
class: "51142500"
classTitle: "Antiparkinson drugs"
family: "51140000"
familyTitle: "Central nervous system drugs"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Mofegiline

**UNSPSC Code**: 51142534
**Class**: [Antiparkinson drugs](Antiparkinson drugs.mdx)
**Family**: [Central nervous system drugs](../Central nervous system drugs.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes a monoamine oxidase inhibitor with the molecular formula C11H13F2N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1FMJ6D8Y1B, chemically known as benzenebutanamine, 4-fluoro-beta-(fluoromethylene)-, (e)- but generally known as mofegiline, which bears US NIH Compound Identifier 6437850. European Medicines Agency schedules Mofegiline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09034MIG. The term MOFEGILINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 8 No. 3 1994, List 34). Most nations schedule mofegiline under HS 29214980 and SITC 51454. As of Q4 2014, MOFEGILINE remains the US FDA Preferred Term for this commodity. Mofegiline bears US NLM identifiers UMLS ID C0208987 and NCI Concept Code C83968. SMILES: C1=CC(=CC=C1CC/C(=C\F)/CN)F.

